{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:12:16Z","timestamp":1790683936638,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,20]]},"DOI":"10.7759\/cureus.113026","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:50:10Z","timestamp":1784566210000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Gastrointestinal Intolerance After Resuming Maintenance-Dose Semaglutide Following Ramadan-Related Treatment Interruption: A Case Report"],"prefix":"10.7759","author":[{"given":"Hafiza","family":"Valizada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihail","family":"Zilbermint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al.. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab. 2024, 110:1-15. 10.1210\/clinem\/dgae719","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0668-z","article-title":"Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist","volume":"57","author":"Hall S","year":"2018","unstructured":"Hall S, Isaacs D, Clements JN. Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clin Pharmacokinet. 2018, 57:1529-1538. 10.1007\/s40262-018-0668-z","journal-title":"Clin Pharmacokinet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S315","article-title":"Incretin-based therapies: viewpoints on the way to consensus","volume":"32 Suppl 2","author":"Nauck MA","year":"2009","unstructured":"Nauck MA, Vilsb\u00f8ll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009, 32 Suppl 2:S223-S231. 10.2337\/dc09-S315","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1613610","article-title":"Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis","volume":"16","author":"Xie X","year":"2025","unstructured":"Xie X, Yang S, Deng S, Liu Y, Xu Z, He B. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. Front Pharmacol. 2025, 16:1613610. 10.3389\/fphar.2025.1613610","journal-title":"Front Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1788698","article-title":"Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies","volume":"17","author":"Alhazmi A","year":"2026","unstructured":"Alhazmi A, le Roux CW. Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. Front Endocrinol. 2026, 17:1788698. 10.3389\/fendo.2026.1788698","journal-title":"Front Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221092681","article-title":"Once-weekly semaglutide for weight management: a clinical review","volume":"38","author":"Fornes A","year":"2022","unstructured":"Fornes A, Huff J, Pritchard RI, Godfrey M. Once-weekly semaglutide for weight management: a clinical review. J Pharm Technol. 2022, 38:239-246. 10.1177\/87551225221092681","journal-title":"J Pharm Technol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70057","article-title":"Recommendations for the management of diabetes during Ramadan applying the principles of the ADA\/ EASD consensus: update 2025","volume":"41","author":"Ibrahim M","year":"2025","unstructured":"Ibrahim M, Ba-Essa EM, Ahmed A, et al.. Recommendations for the management of diabetes during Ramadan applying the principles of the ADA\/ EASD consensus: update 2025. Diabetes Metab Res Rev. 2025, 41:e70057. 10.1002\/dmrr.70057","journal-title":"Diabetes Metab Res Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v15.i4.105478","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes mellitus fasting during Ramadan: a systematic review and meta-analysis","volume":"15","author":"Kamrul-Hasan AB","year":"2025","unstructured":"Kamrul-Hasan AB, Pappachan JM, Ashraf H, Nagendra L, Dutta D, Kuchay MS, Shaikh S. Safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes mellitus fasting during Ramadan: a systematic review and meta-analysis. World J Methodol. 2025, 15:105478. 10.5662\/wjm.v15.i4.105478","journal-title":"World J Methodol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/00185787251372054","article-title":"Missed doses, missed opportunities: readmission due to GLP-1Ra interruption inspires algorithms to improve reinitiation of therapy at discharge","volume":"61","author":"Michelet A","year":"2025","unstructured":"Michelet A, Mowla M, Amo-Brown BA, Rodriguez N, Cavaretta M. Missed doses, missed opportunities: readmission due to GLP-1Ra interruption inspires algorithms to improve reinitiation of therapy at discharge. Hosp Pharm. 2025, 61:10.1177\/00185787251372054","journal-title":"Hosp Pharm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-245. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker DJ","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024, 47:1873-1888. 10.2337\/dci24-0003","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton S","year":"2022","unstructured":"Wharton S, Calanna S, Davies M, et al.. Gastrointestinal tolerability of once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022, 24:94-105. 10.1111\/dom.14551","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.72356","article-title":"Acute systemic complications following high-dose semaglutide reinitiation in an elderly patient","volume":"14","author":"Mehta J","year":"2026","unstructured":"Mehta J, Tai B, Frunzi J. Acute systemic complications following high-dose semaglutide reinitiation in an elderly patient. Clin Case Rep. 2026, 14:e72356. 10.1002\/ccr3.72356","journal-title":"Clin Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/08971900241256775","article-title":"Navigating glucagon-like peptide receptor agonist reinitiation amid access barriers: an adverse drug event case report","volume":"37","author":"Denny O","year":"2024","unstructured":"Denny O, Baron J, Albanese NP. Navigating glucagon-like peptide receptor agonist reinitiation amid access barriers: an adverse drug event case report. J Pharm Pract. 2024, 37:1410-1413. 10.1177\/08971900241256775","journal-title":"J Pharm Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0581-y","article-title":"Population pharmacokinetics of semaglutide for type 2 diabetes","volume":"10","author":"Overgaard RV","year":"2019","unstructured":"Overgaard RV, Delff PH, Petri KC, Anderson TW, Flint A, Ingwersen SH. Population pharmacokinetics of semaglutide for type 2 diabetes. Diabetes Ther. 2019, 10:649-662. 10.1007\/s13300-019-0581-y","journal-title":"Diabetes Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505135-severe-gastrointestinal-intolerance-after-resuming-maintenance-dose-semaglutide-following-ramadan-related-treatment-interruption-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:50:11Z","timestamp":1784566211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505135-severe-gastrointestinal-intolerance-after-resuming-maintenance-dose-semaglutide-following-ramadan-related-treatment-interruption-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.113026","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}